These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644 [TBL] [Abstract][Full Text] [Related]
7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404 [TBL] [Abstract][Full Text] [Related]
10. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nader R; Zhen A; Angel-Korman A; Pavlovich SS; Pogrebinsky A; Doros G; Menn-Josephy H; Stern L; Sanchorawala V; Havasi A Nephrol Dial Transplant; 2022 Jun; 37(7):1281-1288. PubMed ID: 34043009 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Girnius S; Seldin DC; Meier-Ewert HK; Sloan JM; Quillen K; Ruberg FL; Berk JL; Doros G; Sanchorawala V Bone Marrow Transplant; 2014 Mar; 49(3):434-9. PubMed ID: 24317129 [TBL] [Abstract][Full Text] [Related]
13. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823 [TBL] [Abstract][Full Text] [Related]
14. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043 [TBL] [Abstract][Full Text] [Related]
15. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810 [TBL] [Abstract][Full Text] [Related]
16. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Landau H; Smith M; Landry C; Chou JF; Devlin SM; Hassoun H; Bello C; Giralt S; Comenzo RL Leukemia; 2017 Jan; 31(1):136-142. PubMed ID: 27560108 [TBL] [Abstract][Full Text] [Related]
17. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330 [TBL] [Abstract][Full Text] [Related]
18. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986 [TBL] [Abstract][Full Text] [Related]
20. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]